Analysed ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) News Sources
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
04-05-2026
yahoo.com
Atos and CNA strengthen long-term strategic partnership through new multi-year infrastructure services agreement
05-05-2026
yahoo.com
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
06-05-2026
yahoo.com
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
08-05-2026
yahoo.com
ATOS: Initiating Coverage of Atossa Therapeutics; Endoxifen’s Expanding Opportunity from Oncology to Orphan Disease
13-05-2026
yahoo.com
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
14-05-2026
yahoo.com
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
27-05-2026
yahoo.com
What is the current price of ATOSSA THERAPEUTICS INC (ATOS:NASDAQ)?
The current price of ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) is $4.85.
ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) absolute price change since previous trading day?
The absolute price change of ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) since the previous trading day is $-0.26.
ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) percentage price change since previous trading day?
The percentage price change of ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) since the previous trading day is -5.0881%.
What is the most recent average sentiment score for ATOSSA THERAPEUTICS INC (ATOS:NASDAQ)?
The most recent average sentiment score for ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for ATOSSA THERAPEUTICS INC (ATOS:NASDAQ)?
The most recent sentiment for ATOSSA THERAPEUTICS INC (ATOS:NASDAQ) is .
SEC-8K** Filing Available For ATOSSA THERAPEUTICS INC (ATOS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.